Patents by Inventor Punit Upadhyaya
Punit Upadhyaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970553Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: February 4, 2022Date of Patent: April 30, 2024Assignee: BicycleTx LimitedInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Publication number: 20230220008Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: November 14, 2022Publication date: July 13, 2023Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA
-
Publication number: 20230129258Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to two or more second peptide ligands, which bind to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: July 30, 2020Publication date: April 27, 2023Inventors: Punit UPADHYAYA, Johanna LAHDENRANTA, Gemma MUDD, Kevin MCDONNELL
-
Publication number: 20230008076Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: May 12, 2022Publication date: January 12, 2023Inventors: Nicholas KEEN, Kevin MCDONNELL, Peter PARK, Punit UPADHYAYA, Gemma Elizabeth MUDD
-
Patent number: 11542304Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: GrantFiled: October 26, 2020Date of Patent: January 3, 2023Inventors: Liuhong Chen, Rachid Lani, Kevin Mcdonnell, Gemma Mudd, Peter U. Park, Punit Upadhyaya
-
Publication number: 20220306689Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.Type: ApplicationFiled: December 23, 2019Publication date: September 29, 2022Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
-
Publication number: 20220306694Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: March 22, 2022Publication date: September 29, 2022Inventors: Gemma MUDD, Punit Upadhyaya, Kevin Mcdonnell
-
Patent number: 11453703Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: GrantFiled: April 2, 2019Date of Patent: September 27, 2022Assignee: BICYCLETX LIMITEDInventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya, Gemma Mudd
-
Publication number: 20220275053Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold, characterised in that said multimeric binding complex additionally comprises a modifier group conjugated thereto. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137.Type: ApplicationFiled: August 13, 2020Publication date: September 1, 2022Inventors: Punit UPADHYAYA, Gemma Elizabeth MUDD, Kevin MCDONNELL
-
Publication number: 20220257784Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also relates to pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: July 30, 2020Publication date: August 18, 2022Applicants: BicycleTx Limited, BicycleTx LimitedInventors: Punit UPADHYAYA, Johanna LAHDENRANTA, Gemma MUDD, Kevin MCDONNELL
-
Publication number: 20220242911Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: ApplicationFiled: February 4, 2022Publication date: August 4, 2022Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA
-
Publication number: 20220227811Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: ApplicationFiled: February 2, 2022Publication date: July 21, 2022Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA
-
Publication number: 20220194983Abstract: A peptide ligand specific for prostate specific membrane antigen (PSMA) comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.Type: ApplicationFiled: June 19, 2019Publication date: June 23, 2022Inventors: Daniel TEUFEL, Gemma MUDD, Silvia PAVAN, Kevin MCDONNELL, Punit UPADHYAYA
-
Patent number: 11332500Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: GrantFiled: October 5, 2020Date of Patent: May 17, 2022Assignee: BICYCLETX LIMITEDInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell
-
Patent number: 11312749Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: July 29, 2020Date of Patent: April 26, 2022Assignee: BicycleTx LimitedInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Patent number: 11306123Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: July 29, 2020Date of Patent: April 19, 2022Assignee: BICYCLETX LIMITEDInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Publication number: 20220088207Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.Type: ApplicationFiled: December 23, 2019Publication date: March 24, 2022Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
-
Publication number: 20220054646Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of prostrate-specific membrane antigen (PSMA).The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PSMA.Type: ApplicationFiled: December 13, 2019Publication date: February 24, 2022Inventors: Liuhong CHEN, Catherine STACE, Daniel TEUFEL, Punit UPADHYAYA, Edward WALKER
-
Publication number: 20210299210Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.Type: ApplicationFiled: April 2, 2019Publication date: September 30, 2021Inventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya
-
Publication number: 20210101933Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.Type: ApplicationFiled: October 26, 2020Publication date: April 8, 2021Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA